免疫检查点抑制剂相关大疱性类天疱疮研究进展:从发病机制到诊疗策略  

Pathogenesis,diagnosis and treatment of immune checkpoint inhibitor related bullous pemphigoid

作　　者：孙毅 杨骥 SUN Yi;YANG Ji(Department of Dermatology,Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学附属中山医院皮肤科,上海200032

出　　处：《中国临床医学》2025年第2期295-299,共5页Chinese Journal of Clinical Medicine

摘　　要：免疫检查点抑制剂(immune checkpoint inhibitor,ICI)作为一种新型的抗肿瘤药物,可有效提高肿瘤患者的生存率,但也会引起系列不良反应,如皮肤不良反应。ICI治疗可以诱发大疱性类天疱疮(bullous pemphigoid,BP)。虽然ICI治疗后BP发生率低,但对患者生活质量影响较大,也给ICI的继续治疗带来很大挑战。本文对ICI诱发BP的发病机制、患病率、临床表现、诊疗策略及其对肿瘤患者免疫治疗的影响等作一综述。As a new type of anti-tumor therapy,immune checkpoint inhibitor(ICI)can effectively improve the survival rate of tumor patients,but also bring a series of adverse reactions.Among these,immune-related cutaneous adverse events are prevalent.There is a relatively low incidence of bullous pemphigoid(BP)induced by ICI.However,this adverse event may not only negatively impact patient quality of life of patient,but also lead to treatment interruptions or discontinuations.This paper reviews the pathogenesis,prevalence,clinical manifestations,management methods of BP induced by ICI and its effect on tumor immunotherapy.

关 键 词：大疱性类天疱疮 免疫检查点抑制剂 肿瘤免疫治疗 皮肤不良反应 

分 类 号：R758.66[医药卫生—皮肤病学与性病学]